# **Kimia Biosciences Limited**



Regd. Office/Works : Village-Bhondsi, Tehsil-Sohna, Distt. Gurugram (Haryana) E-mail : compliance.kimia@gmail.com & info@kimiabiosciences.com Web : www.kimiabiosciences.com | CIN NO. : L24239HR1993PLC032120 Tel. : +91 9654746544, 9654206544

Ref: KIMIABL/COMP/BSE/21-22/09

June 22, 2021

То

#### **Department of Corporate Affairs- Listing BSE Limited** PhirozJeeJeebhov Towers.

Dalal Street, Fort Mumbai-400001

Scrip Code: 530313 [KIMIABL]

### Sub: Outcome of Board Meeting held on Tuesday, June 22, 2021

Dear Sir,

Pursuant to the provisions of Regulation 30 read with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors of the Company in their meeting held today i.e. Tuesday, June 22, 2021, has inter-alia considered and approved:

a) Audited Financial Statements (Standalone) of the Company for the financial year ended on March 31, 2021;

**b)** Audited Financial Results (Standalone) of the Company for the quarter & year ended on March 31, 2021 along with the Statement of Assets and Liabilities for the year ended on March 31, 2021.


The Board Meeting commenced at 03:00 p.m. and concluded at 04:30 p.m. Kindly take the above information on your records.

Thanking You, Yours faithfully,

Abhishek Kumar PangeyewDelh

For KIMIA BIOSCIENCES LIMITED

PLACE: New Delhi Encl.: a/a



Chartered Accountants

Unit No. 1704, 17th Floor, Tower B, World Trade Tower, DND FLyway, C-01, Sector 16, Noida-201301, Delh: NCR (India) | Ph::(0120) 2970005 Mob. 9205575996 E-mail : newdelhi@singhico.com | Website : www.singhico.com

# Independent Auditor's Report on the Quarterly and Annual Audited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

To the Board of Directors of Kimia Biosciences Limited

#### **Report on the Audit of the Financial Results**

#### Opinion

We have audited the accompanying statement of quarterly and year to date financial results of Kimia Biosciences Limited ("the Company"), for the quarter and year ended March 31, 2021 ("the Statement"), attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement read with notes therein :

- i. is presented in accordance with the requirements of the Listing Regulations in this regard: and
- ii. gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net loss and other comprehensive income for the quarter ended March 31, 2021, the net profit and other comprehensive income for the year ended March 31, 2021 and other financial information of the Company for the quarter and year ended March 31, 2021.

#### **Basis for Opinion**

We conducted our audit in accordance with the Standards on Auditing (SAs), as specified under section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our responsibilities under those Standards are further described in the 'Auditor's Responsibilities for the Audit of the Financial Results' section of our report. We are independent of the Company in accordance with the 'Code of Ethics' issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

#### Management's Responsibilities for the Financial Results


These financial results have been prepared on the basis of the annual financial statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit/loss and other comprehensive income and other financial information of the Company in accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other

Page 1 of 3



-----

AAI INADAI



Chartered Accountants

accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statement, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are also responsible for overseeing the Company's financial reporting process.

#### Auditor's Responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a







Chartered Accountants

going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

• Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Statement that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Statement may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Statement.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### **Other Matter**

The Statement includes the results for the quarter ended March 31, 2021 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2021 and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

Date: June 22, 2021 Place: Noida (Delhi – NCR)



For Singhi & Co. **Chartered Accountants** Firm Reg. No. 302049E

Sp ----

Bimal Kumar Sipani Partner Membership No. 088926 UDIN : **21088926AAAAHX9488** 

#### KIMIA BIOSCIENCES LIMITED

Regd. Office : Village Bhondsi, Tehsil Sohna, Dist. Gurgaon , Haryana - 122102 Phone: +91 9654746544, 9654206544 Email: compliance.kimia@gmail.com & info@kimiabiosciences.com Website: www.kimiabiosciences.com, CIN : L24239HR1993PLC032120



AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2021

S. No.	. Particulars	Quarter ended			Year ended	
5. NO.		31-03-21	31-12-20	31-03-20	31-03-21	31-03-20
		(Audited Refer Note 3)	(Unaudited)	(Audited Refer Note 3)	(Audited)	(Audited)
1	Revenue from Operations	3,601.33	3,434.75	2,125.23	13,271.38	10,628.63
I	Other Income	47.10	55.41	(8.26)	245.62	96.37
	Total Income (I+II)	3,648.43	3,490.16	2,116.97	13,517.00	10,725.00
	Expenses:					
14	a) Cost of materials consumed	2,924.25	2,626.67	1,502.80	10,312.59	7,909.32
	b) Purchase of stock-in-trade	-	-	· ·	-	•
	c) Change in inventories of finished goods and work-in-progres	(99.28)	(98.13)		(627.22)	115.39
	d) Employee benefits expenses	378.62	395.23		1,409.10	1,080.46
	e) Finance costs	100.71	77.44	108.35	339.00	252.88
	f) Depreciation and amortisation expense	59.62	49.90		191.06	166.01
	g) Other expenses	405.94	322.59	296.17	1,339.03	1,078.34
V	Total Expenses (IV)	3,769.86	3,373.70	2,211.62	12,963.56	10,602.40
	Profit/(loss) before exceptional items and Tax (III-V)	(121.43)	116.46	(94.65)	553.44	122.60
VI	Exceptional Items	-	-	-	-	-
VIII	Profit/(loss) Before Tax (VI-VII)	(121.43)	116.46	(94.65)	553.44	122.60
IX	Tax expenses:					
	a) Current Tax	(4.50)	4.50	(15.51)	-	
	b) Current Tax related to earlier years	-	-	-	-	(15.51)
	c) Deferred Tax charge / (reversal)	(26.31)	69.31		43.00	
X	Profit/(loss) for the period (VII-IX)	(90.62)	42.65	(79.14)	510.44	138.11
XI	Other Comprehensive Income					
A.	Items that will not be reclassified to Profit or Loss (Net of Tax)					
1	- Remeasurement of defined benefit plans	(3.99)	-	1.53	(3.99)	(1.16
В.	Items that will be reclassified to Profit or Loss (Net of Tax)	-	-	-	-	-
XII	Total Comprehensive Income for the period (X+XI)	(94.61)	42.65	5 (77.61)	506.45	136.95
XIII	Paid up equity share capital (Face value of Rs.1 per equity	473.13		463.54	473.13	463.54
	share)					
XIV					1,370.52	864.06
XV						
	Basic in Rs.	(0.19	0.09	(0.20)	1.08	0.32
	Diluted in Rs.	(0.19		) (0.17)	1.08	0.28




TATE	ED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2021		
S. No.	Particulars	As at 31-03-2021 (Audited)	As at 31-03-2020 (Audited)
Α	ASSETS	(Audited)	(Audited)
1	Non-Current Assets		
	Property, Plant & Equipment	2827.25	1661.
	Capital Work-in-Progress	577.01	574
	Right of Use Assets	0.00	111
	Other Intangible Assets	9.52	11.
	Financial Assets	9.52	11.
	(i) Other Non Current Financial Assets	17.00	14
	Other Non-current Assets	17.28	14
2	Current Assets	51.70	98.
-	Inventories	0000 70	
	Financial Assets	2368.72	2031.
	(i) Investment		- Contractor and
		5.84	41.
	(ii) Trade Receivables	4176.57	3732
	(iii) Cash and Cash Equivalents	58.66	23
	(iv) Bank balances other than (iii) above	108.73	54
	(v) Other Current Financial Assets	53.21	33.
	Current Tax Assets (Net)	70.12	74.
	Other Current Assets	172.09	104.
	Non-Current Assets Classified as Held for Sale	170.20	
-	Total Assets	10666.90	8566.
	EQUITY & LIABILITIES EQUITY		
	(a) Share Capital	473.13	463.
	(b) Instruments entirely equity in nature (CCPS)	· · · · · · · · · · · · · · · · · · ·	9.
	(c) Other Equity	1370.52	864.
	NON CURRENT LIABILITIES		
1	Financial Liabilities		
	(i) Borrowings	2834.63	2430.
	(ii) Other financial liabilities	448.41	411.
	Deferred Tax Liabilities (Net)	43.80	
	Long Term Provisions	116.94	87.
	Other Non-Current Liabilities	284.66	435.
	CURRENT LIABILITIES	201.00	100.
	Financial Liabilities		
	(i) Borrowings	1312.65	632.
	(ii) Trade Payables	1012.00	032.
	a. Total Outstanding due to Micro and Small Enterprises	01.40	
	b. Total Outstanding due to other than Micro and Small Enterprises	21.10	1.
	(iii) Other Financial Liabilities	3057.53	2654.
		636.87	539.
	Short Term Provisions	5.29	4.
	Other Current Liabilities	61.37	31.
	Total Equity and Liabilities	10666.90	8566.





KIMIA BIOSCIENCES LIMITED Regd. Office : Village Bhondsi, Tehsil Sohna, Dist. Gurgaon , Haryana - 122102 Phone: +91 9654746544, 9654206544 Email: compliance.kimia@gmail.com & info@kimiab Website: www.kimiabiosciences.com, CIN : L24239HR1993PLC032120	iosciences.com	imia
AUDITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 20	021	
STATEMENT OF CASH FLOWS		
Particulars	For the year ended March 31, 2021 (Audited)	For the year ended March 31, 202 (Audited)
A. Cash Flow from Operating Activities		
Net Profit before tax	553.44	122.
Adjustment for :		
Depreciation and amortization expense	191.06	166.
Loss / (profit) on sale/discard of property, plant and equipment (net)	(3.70)	1.
Finance costs	339.00	252.
Gain on fair value of investment in mutual funds	(4.12)	(6.
Interest income	(5.36)	(0.
Deferred revenue income	(101.27)	(87.
Unrealised (gain)/loss on foreign currency transactions and translations	(58.77)	54
Operating Profit Before Working Capital Changes	910.28	503
Adjustments for:		1.1
(Increase )/ Decrease in inventories	(337.49)	(421
(Increase)/ Decrease in trade and other receivables	(534.67)	(923
Increase/ (Decrease) in trade and other payables	554.34	865
Cash Generated From Operations	592.46	23
Less : Income tax paid/ (refunds)	4.24	7
Net Cash From Operating Activities	596.70	30
B. Cash Flow from Investment Activities		
Purchases of property, plant and equipments including intangible assets & capital ad	vances (1,356.08)	(901
Proceeds from sales of property, plant and equipments including intangible assets a capital ad	5.04	3
Net inflow / (outflow) in fixed deposits	(54.59)	62
Purchase of current investments	(04.03)	(39
Proceeds from sales of current investments	40.00	(05
	5.36	11
Interest received      Not Cook Used in Investing Activities	(1,360.27)	(862
Net Cash Used In Investing Activities	(1,380.27)	(002
C. Cash Flow from Financing Activities		A CONTRACTOR
Receipts from non current borrowings	1,665.60	2,293
Repayment of non current borrowings	(1,299.34)	
Net proceeds of current borrowings	680.64	90
Receipt on issuance of equity shares against share warrant	000.04	589
Finance costs paid	(247.85)	(112
Net Cash Used in Financing Activities	799.05	845
iver Gash Useu in Findneing Activities	199.03	040
Net Increase/( Decrease ) in Cash and Cash Equivalents	35.48	13
Cash and Cash Equivalents at the beginning of the period	23.18	g
Cash and Cash Equivalents at the end of the period	58.66	23
ouon and odon Equivalente at the ond of the period		-





AUDI	site: www.kimiabiosciences.com, CIN : L24239HR1993PLC032120 ITED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED MARCH 31, 2021 r Notes The business activity of the Company falls within a single primary business segment viz 'Pharmaceuticals' and hence there is no other reportable				
2	segment as per Ind AS 108 'operating segments'. COVID - 19 pandemic has caused disruption on the global economic and business environment. There is uncertainty with regard to its impact which cannot be reasonably determined at this stage. However, the Company has evaluated and considered to the extent possible the likely impact that may arise from COVID-19 pandemic as well as all event and circumstances upto the date of approval of these financial results on the carrying value of its assets and liabilities as at March 31, 2021. Based on the current indicators of future economic conditions, the Company estimates to recover the carrying amount of its assets and has adequate liquidity to discharge its obligations. These estimates are subject to uncertainty and may be affected by the severity and duration of the pandemic. The Company is continuously monitoring any material changes in future economic conditions.				
3	The figures for the quarter ended March 31, 2021 and March 31, 2020 are the balancing figures between audited figures for the full financial figures and the published year to date figures for the nine months.				
4	The figures for the previous periods have been regrouped/ rearranged, wherever considered necessary, to confirm current period classifications.				
5	The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 22.06.2021				
	June 22, 2021 : New Delhi				

## **Kimia Biosciences Limited**



Regd. Office/Works : Village-Bhondsi, Tehsil-Sohna, Distt. Gurugram (Haryana) E-mail : compliance.kimia@gmail.com & info@kimiabiosciences.com Web : www.kimiabiosciences.com | CIN NO. : L24239HR1993PLC032120 Tel. : +91 9654746544, 9654206544

То

June 22, 2021

### Department of Corporate Affairs- Listing BSE Limited

Phiroz JeeJeebhoy Towers, Dalal Street, Fort Mumbai-400001

Scrip Code: 530313 [KIMIABL]

# Sub: Declaration as per Regulation 33(3)(d) of The Securities and Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended by the SEBI (Listing Obligations and Disclosure Requirements) (Amendment) Regulations, 2016, vide notification No. SEBI/LAD-NRO/GN/2016-17/001 dated May 25, 2016 and Circular no. CIR/CFD/CMD/56/2016 dated May 27, 2016, it is hereby declared that the Annual audit Report (Standalone) for the Financial Year ended March 31, 2021 is with unmodified opinion and does not have any modified opinion/qualification/reservation/adverse remarks.

You are requested to take the above information on your record.

Thanking You, Yours faithfully,

#### For KIMIA BIOSCIENCES LIMITED



Place: New Delhi